Promising Phase III Data For Roche/Ipsen's Taspoglutide Heats Up GLP-1 Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Once-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide.